Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

Estradiol benzoate/estradiol dienanthate/testosterone enanthate benzilic acid hydrazone

From Wikipedia, the free encyclopedia
(Redirected fromClimacteron)
Combination drug
Not to be confused withClimacteric orLactinex.
Pharmaceutical compound
EB/EDE/TEBH
Combination of
Estradiol benzoateEstrogen
Estradiol dienanthateEstrogen
Testosterone enanthate benzilic acid hydrazoneAndrogen;Anabolic steroid
Clinical data
Trade namesClimacteron, Lactimex, Lactostat, Amenose
Other namesEB/EDE/TEBH
Routes of
administration
Intramuscular injection
Identifiers
CAS Number
PubChemCID

Estradiol benzoate/estradiol dienanthate/testosterone enanthate benzilic acid hydrazone (EB/EDE/TEBH), sold under the brand namesClimacteron,Lactimex,Lactostat, andAmenose, is aninjectablecombination medication ofestradiol benzoate (EB), anestrogen,estradiol dienanthate (EDE), an estrogen, andtestosterone enanthate benzilic acid hydrazone (TEBH), anandrogen/anabolic steroid, which is used inmenopausal hormone therapy forperi- andpostmenopausal women and to suppresslactation inpostpartum women.[1][2][3][4][5][6][7] Clinical studies have assessed this formulation.[8][9][10][11][12][13][14][15][16][17][18][19][1]

Climacteron and Amenose contained 1.0 mg EB, 7.5 mg EDE, and 150 mg TEBH (69 mg freetestosterone) and was used to treatmenopausal symptoms.[20][17][21] They were administered byintramuscular injection typically once every 6 weeks but with a range of every 4 to 8 weeks or less frequently.[20] Climacteron was marketed inCanada in 1961 but waswithdrawn in this country in October 2005 due to risk ofendometrial hyperplasia andcancer from unopposed estrogen exposure (i.e., no concomitantprogestogen) as well as induction of supraphysiologicaltestosterone levels.[1][22][23]

Lactimex and Lactostat contained 6 mg EB, 15 mg EDE, and 300 mg TEBH in 2 mL ofcorn oil and were used to suppress lactation.[2][3][24][25] They were administered as a single intramuscular injection afterchildbirth or duringbreastfeeding.[2] They were previously available inGermany and Canada.[2][25]

Estradiol andtestosterone levels following a single intramuscular injection of EB/EDE/TEBH versus 10 mgestradiol valerate have been studied over 28 days.[14][16]

Androgen replacement therapy formulations and dosages used in women
RouteMedicationMajor brand namesFormDosage
OralTestosterone undecanoateAndriol, JatenzoCapsule40–80 mg 1x/1–2 days
MethyltestosteroneMetandren, EstratestTablet0.5–10 mg/day
FluoxymesteroneHalotestinTablet1–2.5 mg 1x/1–2 days
NormethandroneaGinecosideTablet5 mg/day
TiboloneLivialTablet1.25–2.5 mg/day
Prasterone (DHEA)bTablet10–100 mg/day
SublingualMethyltestosteroneMetandrenTablet0.25 mg/day
TransdermalTestosteroneIntrinsaPatch150–300 μg/day
AndroGelGel, cream1–10 mg/day
VaginalPrasterone (DHEA)IntrarosaInsert6.5 mg/day
InjectionTestosterone propionateaTestovironOil solution25 mg 1x/1–2 weeks
Testosterone enanthateDelatestryl, Primodian DepotOil solution25–100 mg 1x/4–6 weeks
Testosterone cypionateDepo-Testosterone, Depo-TestadiolOil solution25–100 mg 1x/4–6 weeks
Testosterone isobutyrateaFemandren M, FolivirinAqueous suspension25–50 mg 1x/4–6 weeks
Mixed testosterone estersClimacteronaOil solution150 mg 1x/4–8 weeks
Omnadren, SustanonOil solution50–100 mg 1x/4–6 weeks
Nandrolone decanoateDeca-DurabolinOil solution25–50 mg 1x/6–12 weeks
Prasterone enanthateaGynodian DepotOil solution200 mg 1x/4–6 weeks
ImplantTestosteroneTestopelPellet50–100 mg 1x/3–6 months
Notes:Premenopausal women produce about 230 ± 70 μgtestosterone per day (6.4 ± 2.0 mg testosterone per 4 weeks), with a range of 130 to 330 μg per day (3.6–9.2 mg per 4 weeks).Footnotes:a = Mostly discontinued or unavailable.b =Over-the-counter.Sources: See template.
Potencies and durations of natural estrogens by intramuscular injection
EstrogenFormDose (mg)Duration by dose (mg)
EPDCICD
EstradiolAq. soln.?<1 d
Oil soln.40–601–2 ≈ 1–2 d
Aq. susp.?3.50.5–2 ≈ 2–7 d; 3.5 ≈ >5 d
Microsph.?1 ≈ 30 d
Estradiol benzoateOil soln.25–351.66 ≈ 2–3 d; 5 ≈ 3–6 d
Aq. susp.2010 ≈ 16–21 d
Emulsion?10 ≈ 14–21 d
Estradiol dipropionateOil soln.25–305 ≈ 5–8 d
Estradiol valerateOil soln.20–3055 ≈ 7–8 d; 10 ≈ 10–14 d;
40 ≈ 14–21 d; 100 ≈ 21–28 d
Estradiol benz. butyrateOil soln.?1010 ≈ 21 d
Estradiol cypionateOil soln.20–305 ≈ 11–14 d
Aq. susp.?55 ≈ 14–24 d
Estradiol enanthateOil soln.?5–1010 ≈ 20–30 d
Estradiol dienanthateOil soln.?7.5 ≈ >40 d
Estradiol undecylateOil soln.?10–20 ≈ 40–60 d;
25–50 ≈ 60–120 d
Polyestradiol phosphateAq. soln.40–6040 ≈ 30 d; 80 ≈ 60 d;
160 ≈ 120 d
EstroneOil soln.?1–2 ≈ 2–3 d
Aq. susp.?0.1–2 ≈ 2–7 d
EstriolOil soln.?1–2 ≈ 1–4 d
Polyestriol phosphateAq. soln.?50 ≈ 30 d; 80 ≈ 60 d
Notes and sources
Notes: Allaqueous suspensions are ofmicrocrystallineparticle size.Estradiol production during themenstrual cycle is 30–640 µg/d (6.4–8.6 mg total per month or cycle). Thevaginalepithelium maturation dosage ofestradiol benzoate orestradiol valerate has been reported as 5 to 7 mg/week. An effectiveovulation-inhibiting dose ofestradiol undecylate is 20–30 mg/month.Sources: See template.
Hormone levels with estradiol benzoate/estradiol dienanthate/testosterone enanthate benzilic acid hydrazone by intramuscular injection

See also

[edit]

References

[edit]
  1. ^abcAl-Imari L, Wolfman WL (September 2012). "The safety of testosterone therapy in women".Journal of Obstetrics and Gynaecology Canada.34 (9):859–865.doi:10.1016/S1701-2163(16)35385-3.PMID 22971455.
  2. ^abcdGeburtshilfe und Frauenheilkunde: Ergebnisse der Forschung für die Praxis. Georg Thieme Verlag. 1969. p. 387,390.[Kelly and Primose and Dodek found the following androgen-estrogen combination to be particularly effective and well-tolerated: 300 mg 3-benzilic acid hydrazone-testosterone-17-enanthate, 15 mg estradiol di-enanthate, 6 mg estradiol benzoate in 2 ml corn oil. This product is sold in Germany under the name Lactimex and has been clinically examined by us.] [...] Of 1200 postpartum patients one quarter stopped breast feeding for a variety of reasons and received an injection of Lactimex (Protina: Benzil acid hydrazon-testosteron-oenanthat 300 mg, Oestradiol-di-oenanthat 15 mg and Oestradiol-benzoate 6 mg in 1.0 ml of oil). In 76% of cases one injection was sufficient and the remaining 24% required a second injection. A second injection was required rarer if the first injection had been longer after delivery. A higher dosage of Lactimex was not necessary in cases with a preceding medical induction with intraveinous Oxytocin (Orasthin). Mothers who had been treated postpartum with methylergobasin did not as often require a second injection. No localized or generalized adverse reaction to the drug was noticed.
  3. ^abZentralblatt für Gynäkologie. J. A. Barth. 1971.The preparation Lactimex (300 mg 3-benzyl hydrazone-testosterone-17-enanthate + 15 mg estradiol-dienanthate + 6 mg estradiol benzoate in 2 ml corn oil) was injected. [...]
  4. ^Ginsburg ES (1999). "Androgen Replacement in Postmenopausal Women". In Seifer DB, Kennard EA (eds.).Menopause. Contemporary Endocrinology. Vol. 18. Humana Press. pp. 209–219.doi:10.1007/978-1-59259-246-3_13.ISBN 978-1-61737-129-5.
  5. ^Greenblatt RB, Barfield WE, Jungck EC (January 1962)."The treatment of the menopause".Canadian Medical Association Journal.86 (3):113–114.PMC 1848811.PMID 13901504.
  6. ^Seifer DB (27 July 1999). Seifer DB, Kennard EA (eds.).Menopause: Endocrinology and Management. Springer Science & Business Media. pp. 183–.doi:10.1007/978-1-59259-246-3.ISBN 978-1-59259-246-3.
  7. ^Hager HH, Kern W, Heinz P, Roth HJ (29 July 2013).Hagers Handbuch der Pharmazeutischen Praxis: Für Apotheker, Arzneimittelhersteller, Ärzte und Medizinalbeamte: Wirkstoffgruppen II Chemikalien und Drogen (A-AL). Springer-Verlag. pp. 157–.ISBN 978-3-662-25655-8.
  8. ^Kelly MJ, Primrose T (December 1960)."Evaluation of a new preparation for the suppression of lactation".Canadian Medical Association Journal.83 (24):1240–1242.PMC 1938994.PMID 13752392.
  9. ^Schneider J, Macarthur JL, Patrick JW, Burton GV (August 1964)."The Suppression of Lactation: An Objective Study".Obstetrics and Gynecology.24 (2):294–297.PMID 14199544.
  10. ^Sherwin BB, Gelfand MM (March 1984). "Effects of parenteral administration of estrogen and androgen on plasma hormone levels and hot flushes in the surgical menopause".American Journal of Obstetrics and Gynecology.148 (5):552–557.doi:10.1016/0002-9378(84)90746-4.PMID 6367474.
  11. ^Sherwin BB, Gelfand MM (January 1985). "Differential symptom response to parenteral estrogen and/or androgen administration in the surgical menopause".American Journal of Obstetrics and Gynecology.151 (2):153–160.doi:10.1016/0002-9378(85)90001-8.PMID 3881960.
  12. ^Sherwin BB (September 1985). "Changes in sexual behavior as a function of plasma sex steroid levels in post-menopausal women".Maturitas.7 (3):225–233.doi:10.1016/0378-5122(85)90044-1.PMID 4079822.
  13. ^Sherwin BB, Gelfand MM (1985). "Sex steroids and affect in the surgical menopause: a double-blind, cross-over study".Psychoneuroendocrinology.10 (3):325–335.doi:10.1016/0306-4530(85)90009-5.PMID 3903822.S2CID 40861936.
  14. ^abcdeSherwin BB, Gelfand MM, Schucher R, Gabor J (February 1987). "Postmenopausal estrogen and androgen replacement and lipoprotein lipid concentrations".American Journal of Obstetrics and Gynecology.156 (2):414–419.doi:10.1016/0002-9378(87)90295-X.PMID 3826177.
  15. ^abcdSherwin BB, Gelfand MM (1987). "Individual differences in mood with menopausal replacement therapy: possible role of sex hormone-binding globulin".Journal of Psychosomatic Obstetrics & Gynecology.6 (2):121–131.doi:10.3109/01674828709016773.ISSN 0167-482X.
  16. ^abSherwin BB (1988). "Affective changes with estrogen and androgen replacement therapy in surgically menopausal women".Journal of Affective Disorders.14 (2):177–187.doi:10.1016/0165-0327(88)90061-4.PMID 2966832.
  17. ^abSherwin BB (1988). "Estrogen and/or androgen replacement therapy and cognitive functioning in surgically menopausal women".Psychoneuroendocrinology.13 (4):345–357.doi:10.1016/0306-4530(88)90060-1.PMID 3067252.S2CID 24695692.
  18. ^Sherwin BB (1994). "The Effect of Sex Steroids on Brain Mechanisms Relating to Mood and Sexuality".Comprehensive Management of Menopause. Clinical Perspectives in Obstetrics and Gynecology. Springer. pp. 327–333.doi:10.1007/978-1-4612-4330-4_31.ISBN 978-1-4612-8737-7.ISSN 0178-0328.
  19. ^Sherwin BB (April 2002)."Randomized clinical trials of combined estrogen-androgen preparations: effects on sexual functioning".Fertility and Sterility.77 (Suppl 4):S49 –S54.doi:10.1016/S0015-0282(02)03002-9.PMID 12007902.
  20. ^ab"Climacteron Drug Information, Professional".Drugs.com. Archived fromthe original on 2 June 2019. Retrieved2 June 2019.
  21. ^Bundesverband der Pharmazeutischen Industrie (Germany) (1974).Rote Liste: Verzeichnis pharmazeutischer Spezialpräparate. Editio Cantor.ISBN 9783871930133.49035 В Amenose® Rp Ampullen Zus.: 1 Amp. 1 ml enth.: Benzilsäurehydrazid-N-testosteron-hydrazon-17-oenanthat 150 mg, Oestradiol-di-oenanthat 7.5 mg. Oestradiolbenzoat 1 mg in öl-Lösg. Ind.: Androgen-Oestrogen-Gemisch. Gegen Ausfallserscheinungen im Klimakterium und nach Ovarektomie. Osteoporose. Kontraind.: A 90, О 5 Dos.: Durchschnittl. alle 6 Wochen 1 Amp. im. 1 Amp. I ml 6.75 3 Amp 17.40 AP.: 10 Amp.
  22. ^Lexchin J (2010)."Drug safety and Health Canada".International Journal of Risk & Safety in Medicine.22 (1):41–53.doi:10.3233/JRS-2010-0490.
  23. ^"Discontinuation of CLIMACTERON® Injection (estradiol dienanthate ⁄ estradiol benzoate and testosterone enanthate benzilic acid hydrazone injection in corn oil)"(PDF).Sandoz Canada Inc. 23 November 2005. Archived fromthe original(PDF) on 2013-01-11. Retrieved2 June 2019.
  24. ^Vorherr H (2 December 2012).The Breast: Morphology, Physiology, and Lactation. Elsevier Science. pp. 201–.ISBN 978-0-323-15726-1.
  25. ^abCompendium of Pharmaceuticals and Specialties. Canadian Pharmaceutical Association. 1983.ISBN 978-0-919115-04-0.LACTOSTAT [...] Each 2 mL of injectable solution contains testosteorne enanthate benzilic acid hydrazone 300 mg, estradiol dienanthate 15 mg, estradiol benzoate 6 mg, benzyl alcohol 7.5% as preservative, benzyl benzoate 0.75 mg, corn oil q.s. Available in 2 mL ampuls, boxes of 25.
Estrogens
ERTooltip Estrogen receptor agonists
Progonadotropins
Antiestrogens
ERTooltip Estrogen receptor antagonists
(incl.SERMsTooltip selective estrogen receptor modulators/SERDsTooltip selective estrogen receptor downregulators)
Aromatase inhibitors
Antigonadotropins
Others
Androgens
(incl.AASTooltip anabolic–androgenic steroid)
ARTooltip Androgen receptoragonists
Progonadotropins
Antiandrogens
ARTooltip Androgen receptorantagonists
Steroidogenesis
inhibitors
5α-Reductase
Others
Antigonadotropins
Others
ERTooltip Estrogen receptor
Agonists
Mixed
(SERMsTooltip Selective estrogen receptor modulators)
Antagonists
GPERTooltip G protein-coupled estrogen receptor
Agonists
Antagonists
Unknown
ARTooltip Androgen receptor
Agonists
SARMsTooltip Selective androgen receptor modulator
Antagonists
GPRC6A
Agonists
Retrieved from "https://en.wikipedia.org/w/index.php?title=Estradiol_benzoate/estradiol_dienanthate/testosterone_enanthate_benzilic_acid_hydrazone&oldid=1292678041"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp